NuSep licences gels
Wednesday, 17 September, 2008
NuSep [ASX: NSP] will accept an offer to license its electrophoresis gel business.
The third party had offered to acquire NuSep's gels business outright or to license the technology.
It was decided that licensing the technology would provide the best return for shareholders, the company said.
The licensing deal should give NuSep enough money to fund this commercialisation of its MF10 and SpermSep separation instruments without any additional fund-raising, and will likely generate an ongoing royalty fee.
NuSep also supplies research grade biological products such as human IgG and albumin.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
